Glossary
Interleukin-6
Interleukin-6 is a real drug target. It's also the number most often waved at people with an inflammatory disease. One trial lowered it in rheumatoid arthritis, and the group it lowered it in didn't beat the others on pain.
What the research found.
One trial ran in 144 rheumatoid arthritis patients across three groups, where interleukin-6 production fell from 8.94 to 8.51. That happened in the cognitive behavioral therapy group only. The P value for the group by time effect was 0.02.
Zautra and colleagues, Journal of Consulting and Clinical Psychology, 2008
In that trial, daily pain fell from 33.50 to 28.63, at a P value of 0.001, and no group beat the others. Daily low mood fell overall as well, again with no group differences. So the cytokine moved in one group while the symptoms moved in all of them.
Zautra and colleagues, Journal of Consulting and Clinical Psychology, 2008
One review covered 72 studies and more than 50,000 people, where broken sleep went with higher interleukin-6 at an effect size of 0.20, with a true value from 0.08 to 0.31. Long sleep went with 0.11, from 0.02 to 0.20. The comparison was against a normal 7 to 8 hours.
One review pooled 21 trials and 8361 people with early rheumatoid arthritis, where tocilizumab with methotrexate, which blocks this cytokine's receptor, had the strongest effect on the strictest response measure. The odds ratio was 4.41, from 2.29 to 8.49. It was also the only drug there with a safety signal, at 5.11 from 2.03 to 12.86.
The 2024 international recommendations for Still's disease are built around blocking interleukin-1 and interleukin-6. They cover diagnosis too, along with short courses of glucocorticoids and watching for complications. So in that disease the cytokine block is the frame the whole guideline is built on rather than one option among several.
Fautrel and colleagues, Annals of the Rheumatic Diseases, 2024
What it is
Interleukin-6 is a cytokine, meaning a small signaling protein immune cells release to affect other cells, and this one drives inflammation. It's among the best studied of the inflammatory cytokines, and part of the reason for that attention is simple. It turned out to be a workable drug target.
Its name reaches patients through treatment rather than through monitoring. A drug class in rheumatology gets described by the cytokine it blocks, so somebody prescribed one of those treatments ends up reading about a signaling protein. That's a fair route to meeting the term, and it can also leave the impression that the molecule is something to track.
It generally isn't one. Interleukin-6 levels aren't measured in routine rheumatology care, and this site holds no source on reading one in a single person. So if a level has been measured for you, the sensible route is to ask whoever ordered it what it means.
What blocking it is used for
Blocking interleukin-6 is now one of the major treatment routes in rheumatology, and the clearest example in our sources comes from Still's disease. The 2024 international recommendations for that condition are built around blocking interleukin-1 and interleukin-6, and they also cover diagnosis, short courses of glucocorticoids, and watching for complications. So that's a guideline whose central advice is a cytokine block.
That's very nearly the whole of what those recommendations cover. A full-text word search found no mention of exercise anywhere in them, and no mention of physical activity, rehabilitation, or physiotherapy either. So in that disease at least, blocking a cytokine isn't one option among many, it's the frame the guideline is built on.
Two drugs in that class now have evidence on this site, and both block the receptor this cytokine signals through. Tocilizumab is the one most trials cover. One review pooled 21 trials and 8361 people with early rheumatoid arthritis, where tocilizumab with methotrexate had the strongest effect of anything it studied on the strictest response measure, at an odds ratio of 4.41 from 2.29 to 8.49.
That review found one safety signal and only one, and it belonged to the same drug. Tocilizumab with methotrexate showed more side effects, at an odds ratio of 5.11 from 2.03 to 12.86, while nothing showed for the other drugs studied. So the strongest effect and the only safety signal came from one combination.
A second review ranked drugs across three outcomes in 88 trials and 31566 people, where tocilizumab ranked relatively well on all three and beat the other active drugs on disease score by between 0.49 and 1.11 points. Sarilumab, which blocks the same receptor, was compared against most other targeted drugs in a third review of 53 trials and showed no significant differences on most outcomes. Those are figures about drugs at treatment doses.
They say nothing about a level measured in your blood, and nothing about anything that moves an average a little. Those are three different claims and only the first has trial evidence behind it. No dose appears on this page.
The trial worth understanding
One trial in our sources measured interleukin-6 alongside symptoms in rheumatoid arthritis, and it's the most useful result on this page. It ran in 144 patients across three groups, where the first got cognitive behavioral therapy for pain, the second got mindfulness meditation with emotion regulation, and the third got education alone. It followed a cytokine and how people felt, which is what makes it useful here.
Interleukin-6 production fell from 8.94 to 8.51 in the cognitive behavioral therapy group only, at a P value of 0.02 for the group by time effect. The authors also say plainly that there was no interleukin-6 effect in the mindfulness group, which didn't support one of the study's main ideas. So at first sight that's a positive cytokine finding, for one of the three groups.
Then the symptoms went the other way. Daily pain fell from 33.50 to 28.63 across the whole trial, at a P value of 0.001, and no group beat the others. Daily low mood fell overall too, again with no group differences, and coping improved across the trial as well.
Why that counts more than the cytokine result
Put those two findings together and something useful falls out of them. The group that moved interleukin-6 wasn't the group that stood out on pain, because no group stood out on pain at all. If the cytokine were tracking the benefit, the two sets of results would agree with each other, and they don't.
So treat a cytokine result and a symptom result as separate claims, and this is the strongest argument on this site for doing so. It isn't an argument from principle. It's a single trial in which the two came apart, in one set of patients over one period, which is worth more than any amount of general caution about mechanism.
Our record adds the usual cautions. The comparison group got education only rather than something matched for attention, interleukin-6 was measured in about two thirds of the sample, and the authors flag that the two active treatments weren't delivered equally well. So this is one useful trial rather than a settled result, and the review notes ask for the numbers to be checked against the paper.
The sleep link
One further finding involves interleukin-6, and it's the kind most often overstated. One review covered 72 studies, some watching people and some testing them, covering more than 50,000 people between them. Broken sleep went with higher interleukin-6 at an effect size of 0.20, with a true value from 0.08 to 0.31, while long sleep went with 0.11, from 0.02 to 0.20, both against a normal seven to eight hours.
Those are small effect sizes, and the design can't establish direction. Poor sleep raising interleukin-6 would give that link, and higher interleukin-6 disturbing sleep would give it too. The people studied were general rather than rheumatology patients, so our record describes the study as supporting plausible biology and nothing stronger.
The step that isn't supported is the chain people build from it, which has three links: improve sleep, lower interleukin-6, and improve the disease. Each link needs its own evidence, and this study provides one weak one. Sleep is worth improving for what sleep does, and the argument for it doesn't need a cytokine to be a good argument.
What to take from this page
Interleukin-6 is a real part of the biology of an inflammatory disease and a real drug target, and neither of those facts makes it a number for a patient to follow. This site holds nothing on reading a single result. So a level measured for you is a question for whoever ordered it.
The specific thing worth taking away is what that trial looks like. A cytokine and a symptom can move independently in one trial, so a claim about one isn't a claim about the other. That single result protects a reader from an overstated claim better than any general warning could.
If somebody has quoted you an interleukin-6 drop as evidence that something works, ask one question: what happened to pain, function, or disease activity in that study? If the answer is that those weren't measured, what you've been shown is a mechanism rather than a benefit. Both are worth something, and only one of them is worth paying for.
Common misconceptions.
Myth. If something lowers my interleukin-6 it's treating my disease.
Reality. The one trial in our sources that lowered it argues against that. Interleukin-6 fell in the cognitive behavioral therapy group only, at a P value of 0.02 for the group by time effect, while daily pain fell across all three groups with no group beating the others. If the cytokine were tracking the benefit, those two results would agree with each other. They don't.
Myth. Interleukin-6 is measured to see how active my disease is.
Reality. Not in routine care, and this site holds no source on doing so. Disease activity gets followed three ways, through joint counts, an inflammation marker like CRP, and your own rating of how you're doing. No reference in our set covers reading an interleukin-6 level in a single person, so if one has been measured for you, what it means is a question for whoever ordered it.
Myth. Blocking interleukin-6 is like reducing it with lifestyle.
Reality. Those two aren't comparable, and the guideline shows the scale of the difference. The 2024 international recommendations for Still's disease are built around blocking interleukin-1 and interleukin-6, which is the treatment itself. A drug that blocks a receptor at a treatment dose does one thing, and something that moves an average a little does another entirely.
Myth. Poor sleep is driving my interleukin-6 up.
Reality. There's a link, it's small, and it points nowhere in particular. One review covered 72 studies and more than 50,000 people, where broken sleep went with higher interleukin-6 at an effect size of 0.20. Higher interleukin-6 disturbing sleep would give that identical link, and those people were general rather than rheumatology patients. So it supports plausible biology without saying what causes what.
Related terms.
- Cytokines, the category this belongs to and why measuring one isn't measuring a disease.
- TNF-alpha, the other cytokine with a major drug class named after it.
- Inflammation, and the difference between the kind you can measure and the kind you have.
- Living with Still's disease, where interleukin-6 inhibition is central to the guideline.
Questions patients ask.
What is interleukin-6?
It's a cytokine, meaning a small signaling protein that immune cells release to affect other cells, and this one drives inflammation. It's among the best studied of them all. Part of the reason for that attention is simple, which is that it turned out to be a workable drug target, so its name turns up in the description of a treatment class rather than because patients have any reason to track it.
Is blocking it a treatment?
Yes, and it's one of the major routes in rheumatology. The 2024 international recommendations for Still's disease are built around blocking interleukin-1 and interleukin-6, and they also cover diagnosis, short courses of glucocorticoids, and watching for complications. Two drugs in that class have evidence on this site, both blocking the receptor this cytokine signals through, and no dose appears anywhere here.
Will my interleukin-6 level be measured?
Not usually, and no reference in our set covers reading one in a single person. Routine care follows disease activity three ways, through joint counts, an inflammation marker like CRP, and your own rating of how you're doing. So if a level has been measured for you, ask whoever ordered it what it changes, because the answer isn't in our sources.
Does anything I do lower it?
One trial ran in 144 rheumatoid arthritis patients, where interleukin-6 production fell in the cognitive behavioral therapy group only, going from 8.94 to 8.51, at a P value of 0.02 for the group by time effect. That's a single finding in one group of one trial. Our record adds two cautions worth knowing, which are that the comparison group got education only rather than something matched for attention, and that interleukin-6 was measured in about two thirds of the sample.
So did that therapy work better than the others?
The pain results say no, and that's the interesting part of it. Daily pain fell from 33.50 to 28.63 across the whole trial, at a P value of 0.001, and no group beat the others. Low mood fell overall too, again with no group differences at all. So one group moved the cytokine, and nothing stood out on how people felt.
What does that tell me about cytokine claims generally?
That a cytokine result and a symptom result can point in different directions, in one set of patients, over one period. So when something gets described as lowering inflammatory signals, ask whether any disease or symptom outcome moved alongside it at all. A cytokine change on its own is a mechanism worth studying, and not a benefit.
Does poor sleep raise it?
There's a small link. One review covered 72 studies and more than 50,000 people, where broken sleep went with higher interleukin-6 at an effect size of 0.20 and long sleep went with 0.11, both against a normal seven to eight hours. Those people were general rather than rheumatology patients, and the design can't say which way the link runs.
References.
- Zautra A; Davis M; Reich J et al. Comparison of cognitive behavioral and mindfulness meditation interventions on adaptation to rheumatoid arthritis for patients with and without history of recurrent depression.. Journal of Consulting and Clinical Psychology. 2008;76:408-421. 10.1037/0022-006X.76.3.408Randomised controlled trial
- Irwin M; Olmstead R; Carroll J. Sleep Disturbance, Sleep Duration, and Inflammation: A Systematic Review and Meta-Analysis of Cohort Studies and Experimental Sleep Deprivation. Biological Psychiatry. 2016;80:40-52. 10.1016/j.biopsych.2015.05.014Systematic review and meta-analysis of 72 cohort studies and experimental sleep deprivation studies
- Fautrel B; Mitrovic S; De Matteis A et al. EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease. Annals of the Rheumatic Diseases. 2024;83:1614-1627. 10.1136/ard-2024-225851International guideline
- Xu H; Li C; Ding R et al. Efficacy and safety of non-conventional synthetic disease-modifying antirheumatic drugs in early active rheumatoid arthritis: a network meta-analysis. BMC Rheumatol. 2025;10:5. 10.1186/s41927-025-00603-xSystematic review and network meta-analysis of randomised controlled trials to February 2025
- Weng C; Xue L; Wang Q et al. Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis. Ther Adv Musculoskelet Dis. 2021;13:1759720X21999564. 10.1177/1759720X21999564Systematic review and network meta-analysis of randomised controlled trials to April 2020 comparing three JAK inhibitors and eight biologic disease-modifying drugs against placebo or conventional synthetic drugs
- Choy E; Freemantle N; Proudfoot C et al. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses. RMD Open. 2019;5:e000798. 10.1136/rmdopen-2018-000798Systematic literature review and network meta-analyses of 24-week efficacy and safety outcomes
- Marsal Barril S; Martin-Martinez MA; Blanco-Garcia FJ et al. Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting. Reumatol Clin (Engl Ed). 2022;18:567-573. 10.1016/j.reumae.2021.12.004Prospective multicenter non-controlled study over 32 weeks
This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.